Cellectis Soars On Transformative Tie-Up With AstraZeneca
The French biotech’s money concerns are over after a lucrative gene editing deal with AstraZeneca brings in an initial cash commitment of $245m and the possibility of many millions more.
You may also be interested in...
Public Company Edition: CARGO Therapeutics grossed $281.3m, giving it the fifth-largest biopharma IPO this year. Also, Alkermes completed its cancer business spinout as Mural Oncology, which launched with $275m, and Xencor sold Ultomiris and Monjuvi royalties for $215m.
CEO Pascal Soriot fielded questions on a wide range of topics – from China to US Medicare drug price negotiations – at a media briefing in New York City.
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.